Anthos Therapeutics Supported Global Survey of 3000+ Patients Prescribed Anticoagulants Detailing Impact of Patient-Relevant Bleeding (PRB) Presented at ISTH 2023
June 26, 2023 07:00 ET
|
Anthos Therapeutics
Patient-Centric Survey Conducted in Collaborationwith StopAfib.org and the National Blood Clot Alliance Findings Suggest “Patient-Relevant Bleeding” More Accurate Than Current Terminology,...
中国および日本の規制当局、アンソス･セラピューティクス (Anthos Therapeutics) の第XI/XIa因子二重阻害剤「アベラシマブ (Abelacimab)」の治験を承認
June 09, 2023 06:18 ET
|
Anthos Therapeutics
心房細動の中国人の患者で抗凝固剤を処方されているのは26％未満であり、また、日本のがん患者の3分の1近くは、十分な治療を受けていない 中国のがん患者の約63％が最初に診断を受けてから6ヶ月以内に静脈血栓塞栓症を発症 アベラシマブはすでに北米、欧州、アジア太平洋地域のその他の諸国の、23ヶ国で試験中 マサチューセッツ州ケンブリッジ発, June 09, 2023 (GLOBE...
中国和日本监管机构批准 Anthos Therapeutics 的双重作用因子 XI/XIa 抑制剂 Abelacimab 的临床试验
June 09, 2023 06:18 ET
|
Anthos Therapeutics
不足 26% 的中国房颤患者接受抗凝剂治疗，而在日本近三分之一的患者未得到充分治疗 在中国约 63% 的癌症患者在确诊后的前 6 个月内出现静脉血栓栓塞症 Abelacimab 已在 23 个国家/地区进行研究 包括北美、欧洲和亚太地区的其他地方 马萨诸塞州剑桥市, June 09, 2023 (GLOBE NEWSWIRE) -- Anthos Therapeutics...
Les autorités réglementaires chinoises et japonaises approuvent les essais cliniques sur l'abelacimab, un inhibiteur du facteur XI/XIa à double action d'Anthos Therapeutics
June 09, 2023 06:18 ET
|
Anthos Therapeutics
Moins de 26 % des patients chinois souffrant de fibrillation auriculaire se voient prescrire un anticoagulant, tandis qu'au Japon, près d'un tiers des patients sont insuffisamment traités Environ...
Zulassungsbehörden in China und Japan genehmigen klinische Studien für doppelt wirkenden Faktor XI/XIa-Inhibitor Abelacimab von Anthos Therapeutics
June 09, 2023 06:18 ET
|
Anthos Therapeutics
Weniger als 26 % der chinesischen Patienten mit Vorhofflimmern bekommen einen Gerinnungshemmer verschrieben, während in Japan fast ein Drittel der Patienten unterbehandelt wird Ungefähr 63 % der...
Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos Therapeutics’ Dual-Acting Factor XI/XIa Inhibitor Abelacimab
June 08, 2023 11:10 ET
|
Anthos Therapeutics
Fewer than 26% of Chinese Patients with Atrial Fibrillation are Prescribed an Anticoagulant, while in Japan Almost One-Third of Patients are Undertreated Approximately 63% of Cancer Patients in China...
New Assessment Scale to Measure Adherence to Oral Anticoagulants Based on Impact of Patient Relevant Bleeding in Atrial Fibrillation Presented at ISPOR 2023
May 09, 2023 09:45 ET
|
Anthos Therapeutics
Anticoagulant Bleeding Burden Adherence Confidence Assessment Scale [ABBA-CAS] Created to Better Address an Important Treatment Gap in the Management of Atrial Fibrillation (AF) and Bring Patient...
New Assessment Scale to Capture Patient Relevant Bleeding to be Presented at ISPOR 2023
May 05, 2023 08:00 ET
|
Anthos Therapeutics
Additional presentation spotlights GARDENIA registry design in patientswith atrial fibrillation and atrial flutter Early Cost-Effectiveness Modeling for Patients with Atrial Fibrillation and Cancer...
First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
January 03, 2023 08:00 ET
|
Anthos Therapeutics
FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation LILAC-TIMI 76 trial is the third Phase 3...
Anthos Therapeutics Announces that Abelacimab Has Received FDA Fast Track Designation for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
September 08, 2022 08:00 ET
|
Anthos Therapeutics
This is the second Fast Track designation issued by the FDA for abelacimab Abelacimab is a dual-acting, once-monthly, fully human monoclonal antibody targeting both Factor XI and Factor XIa with high...